Table 1 |
|
|
Baseline characteristics (mean ± SD) |
|
|
Sex male/female (n) |
10/3 |
|
Age (year) |
64 ± 6 |
|
Diabetes duration (year) |
8 ± 5 |
|
Diabetic values at OGTT yes/no (n) |
12/1 |
|
Lipid lowering drug (= statin) yes/no (n) |
8/5 |
|
Drugs per day |
4.3 ± 2.3 |
|
Anti-hypertensive drugs per day |
1.5 ± 1.5 |
|
Beta-blocker yes/no (n) |
4/9 |
|
Thiazide yes/no (n) |
4/9 |
|
ACE-inhibitor yes/no (n) |
5/8 |
|
Angiotensin-II receptor blocker yes/no (n) |
4/9 |
|
Calcium channel blocker yes/no (n) |
3/10 |
|
Anti-diabetic drugs per day |
1.2 ± 0.9 |
|
Metformin yes/no (n) |
9/4 |
|
Sulfonylurea yes/no (n) |
3/10 |
|
Thiazolidinedione yes/no (n) |
3/10 |
|
Metformin per day (mg) |
1031 ± 864 |
|
HbA1C (%, Mono-S) |
6.6 ± 0.6 |
|
Cholesterol (mmol/l) |
4.4 ± 1.1 |
|
LDL (mmol/l) |
2.9 ± 0.9 |
|
HDL (mmol/l) |
1.28 ± 0.22 |
|
TG (mmol/l) |
1.5 ± 0.7 |
|
CRP (mg/l) |
2.4 ± 1.8 |
|
SBP (mmHg) |
150 ± 21 |
|
DBP (mmHg) |
83 ± 10 |
|
Height (cm) |
171 ± 5 |
|
Weight (kg) |
87 ± 17 |
|
BMI (kg/m2) |
30 ± 7 |
|
Waist (cm) |
103 ± 14 |
|
fP-glucose (mmol/l) |
7.8 ± 1.2 |
|
fP-insulin (pmol/l) |
98 ± 44 |
|
AUC glucose0–120 (mmol/l·min) |
1607 ± 218 |
|
AUC glucose0–120 (mmol/l·min)1 |
667 ± 186 |
|
AUC insulin0–120 (nmol/l·min) |
30 ± 12 |
|
AUC insulin0–120 (nmol/l·min)1 |
18 ± 8 |
|
ISI0,120 (mg·l2/mmol·mU·min) |
40 ± 9 |
|
HOMA2 %B |
65 ± 34 |
|
HOMA2 %S |
59 ± 27 |
|
HOMA2 IR |
2.0 ± 0.8 |
|
|
|
|
1stimulated secretion, area under curve at OGTT with value at 0 minutes as baseline. |
|
|
Jönsson et al. Cardiovascular Diabetology 2009 8:35 doi:10.1186/1475-2840-8-35 |
|
